Inflammatory Bowel Disease Treatment Market Product Driving Factors, Capacity and Growth Rate Analysis to 2028

Posted on 2022-11-24 by researchinsights in Healthcare // 0 Comments

San Francisco, California , USA, Nov 25, 2022 — /EPR Network/ —

Inflammatory Bowel Disease Treatment Industry Overview

The global inflammatory bowel disease treatment market size is expected to reach USD 27.8 billion by 2028, according to a new report by Grand View Research, Inc. The market is expected to expand at a CAGR of 4.8% from 2021 to 2028. Increasing awareness about the disease, rise in geriatric population, and favorable initiatives undertaken by regulatory bodies are anticipated to drive the market growth over the forecast period. For instance, in January 2020, the U.S. FDA allowed ABIVAX to conduct a phase 2B clinical trial of ABX464 on U.S. patients living with moderate-to-severe ulcerative colitis.

Increasing adoption of strategies such as new product development and expansion is expected to drive market growth. For instance, in June 2020, Takeda Pharmaceutical received U.S. FDA approval to manufacture Entyvio (vedolizumab) in its U.S.-based manufacturing facility. The approval is expected to support the growing demand for the drug in the U.S. and nearby countries. Moreover, Takeda pharmaceutical is heavily investing in the development of the market in China.

Inflammatory Bowel Disease Treatment Market Segmentation

Grand View Research has segmented the global inflammatory bowel disease treatment market on the basis of type, drug class, route of administration, distribution channel, and region:

Based on the Type Insights, the market is segmented into Crohn’s Disease and Ulcerative Colitis

Crohn’s disease dominated the market for inflammatory bowel disease treatment and accounted for the largest revenue share of 61.3% in 2020.
The ulcerative colitis segment is anticipated to witness significant growth over the forecast period due to the high patient base and increasing approval of biologics for the treatment of ulcerative colitis.

Based on the Drug Class Insights, the market is segmented into Aminosalicylates, Corticosteroids, TNF inhibitors, IL inhibitors, Anti-integrin, JAK inhibitors, and Others

The TNF inhibitors segment dominated the market for inflammatory bowel disease treatment and accounted for the largest revenue share of 47.8% in 2020.
JAK inhibitors are expected to grow at the fastest rate over the forecast period. The recent approval of Pfizer’s Xeljanz for the treatment of ulcerative colitis and the presence of late-phase pipeline candidates such as upadacitinib, tofacitinib, and filgotinib are expected to drive the JAK inhibitors segment growth over the forecast period.

Based on the Route of Administration Insights, the market is segmented into Oral and Injectable

The injectable segment dominated the market for inflammatory bowel disease treatment and accounted for a revenue share of more than 75.0% in 2020.
The oral route of drug administration is estimated to witness the highest growth rate over the forecast period.

Based on the Distribution Channel Insights, the market is segmented into Hospital Pharmacy, Retail Pharmacy, and Online Pharmacy

The hospital pharmacy segment dominated the market for inflammatory bowel disease treatment and accounted for the largest revenue share of 46.8% in 2020.
The online pharmacy segment is expected to grow at the fastest rate in the next 6 to 8 years.

Inflammatory Bowel Disease Treatment Regional Outlook

North America
Europe
Asia Pacific
Latin America
Middle East & Africa (MEA)

Key Companies Profile & Market Share Insights

Major pharmaceutical companies are largely involved in the development of novel therapies to treat the severe condition of inflammatory bowel disease.

Some prominent players in the global Inflammatory Bowel Disease Treatment market include:

AbbVie Inc.
Biogen
Johnson & Johnson Services, Inc.
Amgen Inc.
UCB S.A.
Novartis AG
Takeda Pharmaceutical Company Limited
Merck & Co., Inc.
Pfizer Inc.
Lilly

Order a free sample PDF of the Inflammatory Bowel Disease Treatment Market Intelligence Study, published by Grand View Research.

About Grand View Research

Grand View Research, U.S.-based market research and consulting company, provides syndicated as well as customized research reports and consulting services. Registered in California and headquartered in San Francisco, the company comprises over 425 analysts and consultants, adding more than 1200 market research reports to its vast database each year. These reports offer in-depth analysis on 46 industries across 25 major countries worldwide. With the help of an interactive market intelligence platform, Grand View Research Helps Fortune 500 companies and renowned academic institutes understand the global and regional business environment and gauge the opportunities that lie ahead.

Matched content

Editor’s pick